Lupin has launched Drospirenone, Ethinyl Estradiol and Levomefolate Calcium tablets and and Levomefolate Calcium tablets used to prevent pregnancy, in the US market.
According to a BSE filing, the company has launched the product after having received approval from the US Food and Drug Administration. The approval was granted in the strengths of 3 mg/ 0.02mg/ 0.451 mg and 0.451 mg. Lupin’s product is a generic equivalent of Bayer’s Beyazs tablets.
Quoting IQVIA MAT June 2018 data, Lupin said Drospirenone, Ethinyl Estradiol and Levomefolate Calcium tablets and Levomefolate Calcium tablets had annual sales of approximately $80.8 million in the US.
Lupin shares were trading 0.38 per cent up at Rs 910.60 apiece on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.